Is the Voided Volume at Office Uroflowmetry Physiological and Reliable? A Comparison between Voiding Diary and Uroflowmetry

2020 ◽  
Vol 104 (11-12) ◽  
pp. 908-913
Author(s):  
Emanuele Rubilotta ◽  
Rita Righetti ◽  
Nicolò Trabacchin ◽  
Pier Paolo Curti ◽  
Elisabetta Costantini ◽  
...  

<b><i>Introduction:</i></b> We compared voided volumes (VV) at voiding diaries (VD) and at uroflowmetry (UF) in men with lower urinary tract symptoms (LUTS). <b><i>Methods:</i></b> This was a prospective, multicenter study. In a cohort of males with LUTS, VV reported in 3-day VD was compared to VV recorded at UF. Demographic data were analyzed. The patients were stratified according to VV. A sub-analysis dividing males by age strata was also performed. <b><i>Results:</i></b> We enrolled 169 patients. Mean VV were higher at UF than at VD in the entire population and in each group, stratified by age. VV significantly decreased with aging. Males with the lowest threshold difference (50 mL) were 29%, with a moderate threshold difference (&#x3c;100 mL) 55.6%, with an intermediate threshold difference 49.1% (51–150 mL), whereas 21.9% of men had a large threshold difference (&#x3e;150 mL). <b><i>Discussion/Conclusion:</i></b> VV correlation between VD and UF was poor. A large part of men performed UF with VV which were poorly comparable to the habitual VV assessed by 3-day VD. Therefore, our results indicate the relevance to obtain more than 1 UF in these patients.

2014 ◽  
Vol 48 (6) ◽  
pp. 554-558 ◽  
Author(s):  
Jerry G. Blaivas ◽  
Johnson F. Tsui ◽  
Michael Amirian ◽  
Buddima Ranasinghe ◽  
Jeffrey P. Weiss ◽  
...  

2021 ◽  
Vol 9 ◽  
pp. 205031212110473
Author(s):  
Tae Wook Kang ◽  
Jae Hung Jung ◽  
Dong Wook Kim ◽  
Kwang Ho Lee ◽  
Hyun Chul Chung

Purpose: To evaluate efficacy of 0.4 mg tamsulosin monotherapy in patients with benign prostatic hyperplasia with moderate-to-severe International Prostate Symptom Score. Material and methods: From May 2015 to May 2017, 102 patients were analyzed, retrospectively. The patients were classified into three groups according to the combination of medication (tamsulosin 0.4 mg vs tamsulosin 0.4 mg + solifenacin 5 mg vs tamsulosin 0.4 mg + mirabegron 50 mg). Baseline characteristics (e.g. age, body weight, height, and underlying medical disease) were collected. International Prostate Symptom Score, prostate specific antigen, prostate volume, peak urinary flow rate (Qmax), voided volume, and post-voided volume before after treatment were evaluated. Results: We classified and analyzed the patients into three groups depending on the medication. And there were no significant differences between all parameters among the groups. Voided volume at 3 months after treatment in each group was 170.54 ± 125.83, 121.55 ± 46.19, and 274.63 ± 132.30 ( p = 0.019). Differences of voiding symptom score and difference of post-voided volume among the groups before after treatment was 5.00 ± 5.42, 1.92 ± 3.92, and 0.11 ± 5.11 and 8.37 ± 34.32, 0.78 ± 14.86, −33.63 ± 28.58 ( p = 0.037, p = 0.007). Conclusion: We think tamsulosin monotherapy will be feasible as a first-line therapy for the patients with benign prostatic hyperplasia who has struggled with moderate-to-severe lower urinary tract symptoms.


Sign in / Sign up

Export Citation Format

Share Document